Cytokine‑induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature

Li,Wei; Xu,Lin  Ping; Zhao,Ling  Di; Wang,Li; Zhang,Yong; Gao,Quan  Li; Mai,Ling

doi:10.3892/ol.2013.1200

Cytokine‑induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature

Authors:
- Wei Li
- Lin Ping Xu
- Ling Di Zhao
- Li Wang
- Yong Zhang
- Quan Li Gao
- Ling Mai
View Affiliations

Affiliations: Department of Biotherapy, The Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, P.R. China, Department of Science Research, Henan Cancer Hospital, Zhengzhou 450003, P.R. China, Institute of Tumor Research, Henan Cancer Hospital, Zhengzhou 450003, P.R. China
Published online on: February 19, 2013 https://doi.org/10.3892/ol.2013.1200
Pages: 1427-1429

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with advanced pancreatic adenocarcinoma have a poor prognosis, and to date, no treatment method has had a significant impact on the disease. In general, the mean overall survival time of such patients receiving conventional chemotherapy and radiotherapy is <6 months. In the present case report, a patient with advanced pancreatic adenocarcinoma experienced a longer progression‑free survival (PFS) of >19 months, following cytokine‑induced killer (CIK) cell therapy. To the best of our knowledge, no study has previously described such a beneficial effect on patients only receiving CIK cell immunotherapy. Based on these findings, CIK cell therapy may be a potential treatment regimen that is capable of leading to an improved prognosis in certain patients with advanced pancreatic adenocarcinoma.

View Figures

View References

1	Laheru D and Jaffee EM: Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer. 5:459–467. 2005. View Article : Google Scholar : PubMed/NCBI
2	Vizio B, Novarino A, Giacobino A, et al: Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med. 4:70–78. 2012.PubMed/NCBI
3	Franssen B and Chan C: Pancreatic Cancer: The surgeons point of view. Rev Gastroenterol Mex. 76:353–361. 2011.PubMed/NCBI
4	Janes RJ, Niederhuber JE, Chmiel JS, et al: National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg. 223:261–272. 1996. View Article : Google Scholar : PubMed/NCBI
5	Moss RA and Lee C: Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther. 3:111–127. 2010. View Article : Google Scholar : PubMed/NCBI
6	Koido S, Homma S, Takahara A, et al: Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol. 2011:2675392011. View Article : Google Scholar : PubMed/NCBI
7	Dougan M and Dranoff G: Immune therapy for cancer. Annu Rev Immunol. 27:83–117. 2009. View Article : Google Scholar
8	Hontscha C, Borck Y, Zhou H, et al: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
9	Schwaab T, Schwarzer A, Wolf B, et al: Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 15:4986–4992. 2009.PubMed/NCBI
10	Liu L, Zhang W, Qi X, et al: Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 18:1751–1759. 2012. View Article : Google Scholar : PubMed/NCBI
11	Schmidt-Wolf IG, Lefterova P, Mehta BA, et al: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
12	Werner J and Buchler MW: management of pancreatic cancer: recent advances. Dtsch Med Wochenschr. 136:1807–1810. 2011.PubMed/NCBI
13	Ng J, Zhang C, Gidea-Addeo D, et al: Locally advanced pancreatic adenocarcinoma: update and progress. JOP. 13:155–158. 2012.PubMed/NCBI
14	Cardenes HR, Chiorean EG, Dewitt J, et al: Locally advanced pancreatic cancer: current therapeutic approach. Oncologist. 11:612–623. 2006. View Article : Google Scholar : PubMed/NCBI
15	Karimi M, Cao TM, Baker JA, et al: Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 175:7819–7828. 2005.PubMed/NCBI
16	Verneris MR, Karami M, Baker J, et al: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 103:3065–3072. 2004.PubMed/NCBI
17	Li R, Wang C, Liu L, et al: Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 61:2125–2133. 2012. View Article : Google Scholar : PubMed/NCBI
18	Schmidt-Wolf IG, Lefterova P, Mehta BA, et al: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
19	Joshi PS, Liu JQ, Wang Y, et al: Cytokine-induced killer T cells kill immature dendritic cells by tcr-independent and perforin-dependent mechanisms. J Leukoc Biol. 80:1345–1353. 2006. View Article : Google Scholar : PubMed/NCBI
20	Mesiano G, Todorovic M, Gammaitoni L, et al: Cytokine-induced killer (cik) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 12:673–684. 2012. View Article : Google Scholar : PubMed/NCBI
21	Shi L, Zhou Q, Wu J, et al: Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 61:2251–2259. 2012. View Article : Google Scholar : PubMed/NCBI